Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurodegeneration in multiple sclerosis: defining the problem.

Robert P Lisak1

  • 1Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine and the Detroit Medical Center, Detroit, Michigan 48201, USA. rlisak@med.wayne.edu

Neurology
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis: Potential Implication in Progressive Disease Biology.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Use of Therapeutic Plasma Exchange in Autoimmune Neuromuscular Disorders.

Muscle & nerve·2026
Same author

Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis.

Neuroimmunology and neuroinflammation·2025
Same author

Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.

Journal of neuroimmunology·2024
Same author

Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis.

EBioMedicine·2023
Same author

MOG Antibody-Associated Disease and Thymic Hyperplasia: From the National Multiple Sclerosis Society Case Conference Proceedings.

Neurology(R) neuroimmunology & neuroinflammation·2022
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Neurodegeneration in multiple sclerosis (MS) starts earlier than previously thought, affecting axons beyond white matter lesions. Understanding this early neuron loss is crucial for developing effective neuroprotective therapies to halt and reverse damage.

Area of Science:

  • Neuroscience
  • Neurology
  • Immunology

Background:

  • Neurodegeneration in multiple sclerosis (MS) is now understood to commence earlier than previously recognized.
  • Axon loss, a cause of permanent deficits, occurs beyond visibly affected central nervous system (CNS) white matter.
  • Continuous neuron loss happens irrespective of fluctuating clinical symptoms in MS.

Purpose of the Study:

  • To precisely define the scope of neurodegeneration in multiple sclerosis (MS).
  • To inform the development of experimental and clinical strategies for neuroprotection.
  • To identify approaches that can halt and reverse neuron damage in MS.

Main Methods:

  • Review of cellular interactions in normal-appearing and affected CNS tissue.
  • Analysis of the distribution of axon loss.

Related Experiment Videos

  • Consideration of the temporal dynamics of neuron loss relative to clinical symptoms.

    • Main Results:

    • Evidence suggests neurodegeneration in MS is an early and pervasive process.
    • Axon loss is not confined to areas of white matter abnormality.
    • Neuron loss occurs continuously, independent of clinical relapses and remissions.

    Conclusions:

    • Early and widespread neurodegeneration necessitates a reevaluation of MS progression.
    • Developing effective neuroprotective therapies requires a comprehensive understanding of early pathological changes.
    • Further research into cellular interactions is vital for advancing neuroprotective strategies in MS.